Journal of Gastrointestinal Surgery

, Volume 13, Issue 4, pp 793–797 | Cite as

Resolution of Systemic Hypertension after Laparoscopic Gastric Bypass

  • Marcelo W. Hinojosa
  • J. Esteban Varela
  • Brian R. Smith
  • Fredrick Che
  • Ninh T. Nguyen
Open Access
original article

Abstract

Background

Hypertension is a well-recognized and treatable risk factor for coronary heart disease and is one of the most common comorbidities associated with obesity. The aim of this study was to characterize the clinical outcome of a cohort of patients with documented hypertension who underwent laparoscopic gastric bypass.

Methods

Ninety-five obese patients with documented hypertension and being treated with antihypertensive medication(s) underwent laparoscopic gastric bypass. Main outcome measures included length of hypertensive condition, changes in systolic and diastolic blood pressures, and changes in antihypertensive medication(s) at follow-up.

Results

There were 69 (72%) females with a mean preoperative body mass index of 47 kg/m2. The mean duration of hypertension was 73 ± 70 months. The mean excess body weight loss at 12 months was 66%. The mean systolic blood pressure significantly decreased from 140 ± 17 mmHg preoperatively to 120 ± 18 mmHg at 12 months (p < 0.01). The mean diastolic blood pressure also significantly decreased from 80 ± 11 mmHg preoperatively to 71 ± 8 mmHg at 12 months (p < 0.01). At 12 months follow-up, 44 (46%) patients had complete resolution of hypertension while 18 (19%) patients had improvement. Patients with complete resolution had a shorter duration of disease as compared to patients without resolution (53 vs. 95 months, respectively, p = 0.01).

Conclusion

Weight loss associated with laparoscopic gastric bypass substantially improves and/or resolves hypertension in the majority of patients. Improvement of hypertension occurs as early as 1 month postoperatively and is more frequently in patients with a shorter preoperative duration of disease.

Keywords

Bariatric surgery Morbid obesity Systemic hypertension Gastric bypass 

Background

The prevalence of obesity in the USA is on the rise. It is estimated that one-third of the adult population in the USA is obese.1,2 Obesity has been associated with a number of comorbid conditions such as hypertension, hyperlipidemia, obstructive sleep apnea, type 2 diabetes, arthritis, and coronary artery disease.3,4 Of these conditions, hypertension is the most common comorbidity associated with obesity. The risk of developing hypertension has been found to increase with increasing weight class.5 Hypertension alone is a cardiovascular risk factor but when combined with obesity, there is a substantially higher cardiovascular risk.6 A number of studies have shown that weight reduction is associated with significant improvement or remission of many of the obesity-related comorbid conditions and can lead to a decrease in the predicted cardiovascular risk.7, 8, 9, 10, 11, 12, 13 Surgery is currently the most successful method for sustained weight loss in the morbidly obese.3,14 There are a number of surgical approaches to weight loss which include both malabsorptive and/or restrictive mechanisms. Currently, in the USA, Roux-en-Y gastric bypass is the most commonly performed bariatric procedure. The aim of this study was to characterize the clinical outcomes, specifically with regard to improvement or resolution of hypertension, of a cohort of morbidly obese hypertensive patients who underwent laparoscopic Roux-en-Y gastric bypass.

Materials and Methods

Patient Identification and Selection

We performed a retrospective analysis of our prospectively collected bariatric database of 95 patients with documented hypertension who underwent laparoscopic gastric bypass with a minimum follow-up of 12 months. This group of patients represented 38% of the cohort of patients who underwent gastric bypass between 2003 and 2006. All patients met the 1991 National Institute of Health Consensus Conference guidelines for bariatric surgery. Our surgical technique consisted of constructing a 15- to 20-ml transected gastric pouch with a 150-cm Roux limb. The gastrojejunal anastomosis was performed in an end-to-side fashion using a circular stapler. Approval for this retrospective study was obtained from the University of California Medical Center Institutional Review Board.

Baseline clinical data including patient characteristics, length of hypertensive condition, weight, antihypertensive medication(s) requirement, and blood pressure readings were obtained at the initial clinic visit. Each patient underwent three blood pressure measurements and the average reading was recorded by one of two medical assistants. All patients with a preexisting diagnosis of hypertension and currently being treated with antihypertensive medication(s) were included in this review. All patients were followed postoperatively in an outpatient clinic at 1 week, 1 month, and then at 3 months interval. Medication adjustments in the postoperative period were made at the discretion of each patient’s primary care physician. There was no established protocol for the reduction or discontinuation of antihypertensive medication(s). Improvement of hypertension was defined as a decrease in medication requirement and a normal blood pressure (systolic pressure <140 mmHg and diastolic pressure <80 mmHg). Resolution of hypertension was defined as a normal blood pressure and discontinuation of all antihypertensive medications. The Assessment of Obesity-Related Comorbidity (AORC) scale was used to objectively quantify preoperative and postoperative degrees of hypertension.15 The scale of 0 was defined as not present; a scale of 1 was defined as borderline/intermittent diagnosis not confirmed; a scale of 2 was defined as controlled by diet and exercise; a scale of 3 was defined as treatment with a single medication; and a scale of 4 was defined as treatment with multiple medications.

Statistical Analysis

Continuous variables were expressed as mean ± standard deviation and were analyzed using two-sample t tests. Categorical variables were analyzed using Fisher’s exact tests or the Chi-square tests with Yates’ correction when appropriate. Statistical analysis was performed using SPSS statistical software, version 12.0 (SPSS Inc., Chicago, IL, USA). A p value of less than 0.05 was considered significant.

Results

There were 95 morbidly obese patients with documented hypertension who underwent laparoscopic gastric bypass with complete data at 1-year follow-up (Table 1). There were 26 (28%) males and 69 (72%) females with a mean age of 47 ± 9 years (range 26–64 years). The mean body mass index was 47 ± 8 kg/m2. The mean excess body weight loss was 23% at 1 month, 38% at 3 months, 55% at 6 months, 62% at 9 months, and 66% at 1 year. There were no in-hospital or 30-day mortalities. The mean duration of hypertension prior to gastric bypass was 73 ± 70 months. Preoperatively, all patients were on at least a single antihypertensive medication; 57 patients (60%) have a hypertension AORC scale of 3 and 38 patients (40%) have a hypertension AORC Scale of 4.
Table 1

Characteristics and Outcomes of Hypertensive Morbidly Obese Patients who Underwent Laparoscopic Gastric Bypass

No. of hypertension patients (N)

95

No. of females (%)

69 (72)

Mean age (years)

47 ± 9

Baseline body mass index (kg/m2)

47 ± 8

Mean duration of disease (months)

73 ± 70

No. of patients with preoperative hypertension AORC scale = 3a (%)

57 (60)

No. of patients with preoperative hypertension AORC scale = 4b (%)

38 (40)

30-day or in-hospital mortality (%)

0 (0)

Mean excess body weight loss at 1 month (%)

23 ± 9

Mean excess body weight loss at 12 months (%)

66 ± 16

AORC scale Assessment of Obesity-Related Comorbidity scale

aTreatment of hypertension with a single medication

bTreatment of hypertension with multiple medications

There was a significant reduction in mean systolic blood pressure from 140 ± 17 mmHg preoperatively to 123 ± 18 mmHg at 1 month and ultimately to 120 ± 18 mmHg at 12 months postoperatively, p < 0.01 (Fig. 1). There was also a significant reduction in the mean diastolic blood pressure from 80 ± 11 mmHg preoperatively to 75 ± 10 mmHg at 1 month and 71 ± 8 mmHg at 12 months postoperatively, p < 0.01. At 1 month postoperatively, 24 (25%) patients had complete resolution of hypertension while 34 (36%) had improvement (Fig. 2). At 12 months postoperatively, 44 (46%) patients had complete resolution while 18 (19%) patients had improvement of hypertension. Patients with complete resolution of hypertension at 1 month postoperatively had a shorter duration of disease as compared to those without resolution (38 ± 45 months vs. 87 ± 74 months, p < 0.01). At 12 months postoperatively, the mean duration of preexisting hypertension was also lower for patients with resolution of hypertension compared to patients who did not have resolution, 53 ± 52 months vs. 95 ± 81 months, respectively, p = 0.03 (Table 2). The median percent excess body weight loss was 57% at 12 months. Of the patients who achieved excess body weight loss above the median value, 72% had resolution of hypertension as compared to 19% had resolution for patients who did not achieve the median weight loss (p < 0.01). The 12 months, mean systolic blood pressure was lower in patients who had resolution of hypertension when compared to those without resolution, 114 ± 17 mmHg vs. 128 ± 12 mmHg (p = 0.02) and the diastolic blood pressure was also lower in patients who had resolution of condition, 70 ± 10 mmHg vs. 80 ± 11 mmHg, respectively, p < 0.01. At 12 months, 46% of patients have a hypertension AORC scale of 0 while 7% and 46% have an AORC scale of 3 and 4, respectively. Age, gender, race, preoperative BMI, preoperative blood pressure, preoperative AORC scale, and preoperative medication requirements were similar between those with resolution of hypertension and those without.
Figure 1

Mean change in systolic and diastolic blood pressure in morbidly obese patients with documented hypertension who underwent laparoscopic gastric bypass. *p < 0.05, compared to baseline value. Base preoperative blood pressure.

Figure 2

Improvement or resolution of hypertension in morbidly obese patients with documented hypertension who underwent laparoscopic gastric bypass.

Table 2

Comparisons of Patient with Complete Resolution of Hypertension vs. Patients without Resolution at 12 Months Postoperatively

 

Resolution (N = 44)

No resolution (N = 51)

Mean age (years)

46 ± 9

49 ± 8

No of females (%)

33 (75)

34 (67)

No. of Hispanics (%)

8 (18)

6 (12)

No. of African Americans (%)

3 (7)

5 (10)

Mean preoperative no. of antihypertensive medications

2 ± 1

2 ± 1

Mean duration of hypertensive disease (months)

55 ± 52*

93 ± 81

Preoperative systolic blood pressure (mmHg)

136 ± 16

142 ± 17

Systolic blood pressure at 12 months (mmHg)

114 ± 17*

128 ± 12

Preoperative diastolic blood pressure (mmHg)

78 ± 10

81 ± 12

Diastolic blood pressure at 12 months (mmHg)

70 ± 10*

80 ± 11

*p < 0.05, compared to patients without resolution of hypertension

Discussion

The main finding of this study is that morbidly obese patients with hypertension who underwent laparoscopic gastric bypass had a significant improvement in both systolic and diastolic blood pressure at 12 months after surgery and reduction in the need for anti-hypertensive medications. Improvement in blood pressure was seen as early as 1 month postoperatively. At 1 month after gastric bypass, there was 25% complete resolution of hypertension and at 12 months postoperatively, 44% of individuals had complete resolution. Individuals with complete resolution of hypertension had shorter duration of disease compared to those without resolution.

Hypertension is the most common comorbidity associated with obesity. Numerous mechanisms have been proposed as to how obesity contributes to the development of hypertension. Some of the proposed mechanisms include alteration in the renin–angiotensin–aldosterone system, increased sympathetic nervous system activity, development of insulin resistance, hyperleptinemia and leptin resistance, altered coagulation factors, inflammation, and endothelial dysfunction.16 Most likely, the mechanism for hypertension in the obese is multifactorial. The incidence of hypertension in patients who undergo bariatric surgery ranges from 40% and up to 70% depending on the definition for hypertension.10,12,16, 17, 18, 19 For example, Fernstrom et al., in their evaluation of 285 gastric bypass patients, included patients with stage 1 hypertension (systolic blood pressure >140 mmHg and diastolic >90 mmHg) without anti-hypertensive medications and thus found a 57% incidence of hypertension within their study group.20

The combination of obesity and hypertension places patients at a higher cardiovascular risk than those patients without hypertension. This risk can be markedly reduced after resolution of hypertension following weight loss.19 In a large population-based study of 197 patients, Batsis et al. found a significant improvement in hypertension, diabetes, and dyslipidemia, leading to a decrease in the estimated 10-year risk of cardiovascular events in morbidly obese patients after gastric bypass.13 In our study, the weight loss following laparoscopic gastric bypass led to significant decrease in both systolic and diastolic blood pressure. At 12 months postoperatively, our cohort had a 14% reduction (by 20 mmHg) in the systolic blood pressure and an 11% reduction (by 9 mmHg) in the diastolic blood pressure. Fernstrom et al., in a retrospective review of 347 patients who underwent either gastric bypass or vertical band gastroplasty, reported only a modest reduction in systolic (3 mmHg) and diastolic (4 mmHg) blood pressure.20 Outcome data from the Swedish Obese Subjects (SOS) study, which compared 1,157 obese patients who underwent bariatric surgery to 1,031 obese-matched medically treated patients, revealed marked reductions in both weight and blood pressure in the surgical group when compared to the medically treated group.21 The surgically treated group had an improvement of 11 mmHg for systolic blood pressure and 7 mmHg for diastolic blood pressure. However, by year 8, there was no difference between the blood pressures of the surgical group vs. the medically treated group.21 However, in a small subset of patients who underwent gastric bypass in the SOS study, weight loss and improvement of hypertension persisted. Other studies have also reported similar results with continual improvement/resolution of hypertension after 1 year.20

Multiple studies have shown that weight loss after gastric bypass will lead to the resolution of multiple comorbidities. In our study, 46% of patients had complete resolution of hypertension with 65% of patients showed improvement or resolution at 12 months. Sugerman et al. reported a 69% resolution of hypertension in their analysis of 1,025 gastric bypass patients, which was maintained out to 5 to 7 years.18 Similarly, Fernstrom et al. found 50% resolution of hypertension after surgery with no relapse at 12 to 18 months follow-up. In a large meta-analysis that included 136 studies and 2,115 gastric bypass patients, Buchwald et al. found that 75% of patients had resolution and 87% had resolution or improvement of hypertension.3 In a retrospective analysis of 55 veterans who underwent gastric bypass, Huerta et al. found 89% resolution of hypertension following the gastric bypass.22 Maggard and colleagues reviewed 19 studies that reported changes in hypertension after bariatric surgery and found that resolution or improvement of hypertension occurred in 25% to 75% of patients while improvement was seen in 95% to 100% of patients following bariatric surgery.14

Our study also showed a relationship between the length of preexisting hypertension and the likelihood for resolution of the disease. The mean length of condition was significantly lower in patients who had complete resolution of hypertension when compared to those without resolution. At 1 month after gastric bypass, patients who experienced resolution of hypertension had a shorter mean length of hypertension at 38 months compared to 87 months in patients without resolution. The same was true at 12 months; patients with resolution of hypertension had a significantly shorter length of hypertension when compared to those without resolution. These findings suggest that a length of preexisting hypertension of less than 4 years may be predictive for those patients who will not only have resolution of hypertension following gastric bypass but those who will resolve sooner. These findings also suggest that the longer hypertension persists, the more functional and structural changes accompany the disease and the more difficult for the disease to resolve.23,24 This was previously proposed by Sugerman et al.18 Given this finding, perhaps bariatric surgery should be offered much sooner to morbidly obese patients with hypertension, as length of preexisting condition is an important factor predicting its resolution.

Conclusion

In conclusion, weight loss associated with laparoscopic gastric bypass significantly improves systolic and diastolic blood pressure and is effective in leading to discontinuation or a marked reduction of hypertensive medication requirements in a large proportion of morbidly obese hypertensive patients. These findings occur as early as 1 month postoperatively and seem to be associated with the duration of preexisting disease. Moreover, patients with a length of preexisting hypertension of less than 4 years are more likely to have resolution of hypertension. This suggests that perhaps patients with morbid obesity and hypertension should be offered surgical weight loss earlier in their disease process.

Notes

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

  1. 1.
    Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006;295(13):1549–1555. doi:10.1001/jama.295.13.1549.PubMedCrossRefGoogle Scholar
  2. 2.
    Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA 2004;291(23):2847–2850. doi:10.1001/jama.291.23.2847.PubMedCrossRefGoogle Scholar
  3. 3.
    Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292(14):1724–1737. doi:10.1001/jama.292.14.1724.PubMedCrossRefGoogle Scholar
  4. 4.
    Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P, Razak F, Sharma AM, Anand SS. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case–control study. Lancet 2005;366(9497):1640–1649. doi:10.1016/S0140-6736(05)67663-5.PubMedCrossRefGoogle Scholar
  5. 5.
    Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999;282(16):1523–1529. doi:10.1001/jama.282.16.1523.PubMedCrossRefGoogle Scholar
  6. 6.
    Thomas F, Bean K, Pannier B, Oppert JM, Guize L, Benetos A. Cardiovascular mortality in overweight subjects: The key role of associated risk factors. Hypertension 2005;46(4):654–659. doi:10.1161/01.HYP.0000184282.51550.00.PubMedCrossRefGoogle Scholar
  7. 7.
    Nguyen NT, Varela E, Sabio A, Tran CL, Stamos M, Wilson SE. Resolution of hyperlipidemia after laparoscopic Roux-en-Y gastric bypass. J Am Coll Surg 2006;203(1):24–29. doi:10.1016/j.jamcollsurg.2006.03.019.PubMedCrossRefGoogle Scholar
  8. 8.
    Nguyen NT, Varela JE, Sabio A, Naim J, Stamos M, Wilson SE. Reduction in prescription medication costs after laparoscopic gastric bypass. Am Surg 2006;72(10):853–856.PubMedGoogle Scholar
  9. 9.
    Varela JE, Hinojosa MW, Nguyen NT. Resolution of obstructive sleep apnea after laparoscopic gastric bypass. Obes Surg 2007;17(10):1279–1282. doi:10.1007/s11695-007-9228-6.PubMedCrossRefGoogle Scholar
  10. 10.
    Pajecki D, Dalcanalle L, Souza de Oliveira CP, Zilberstein B, Halpern A, Garrido AB, Cecconello I. Follow-up of Roux-en-Y gastric bypass patients at 5 or more years postoperatively. Obes Surg 2007;17(5):601–607. doi:10.1007/s11695-007-9104-4.PubMedCrossRefGoogle Scholar
  11. 11.
    Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999;7(5):477–484.PubMedGoogle Scholar
  12. 12.
    Yan E, Ko E, Luong V, Wang HJ, Romanova M, Li Z. Long-term changes in weight loss and obesity-related comorbidities after Roux-en-Y gastric bypass: a primary care experience. Am J Surg 2008;195(1):94–98. doi:10.1016/j.amjsurg.2007.01.036.PubMedCrossRefGoogle Scholar
  13. 13.
    Batsis JA, Romero-Corral A, Collazo-Clavell ML, Sarr MG, Somers VK, Brekke L, Lopez-Jimenez F. Effect of weight loss on predicted cardiovascular risk: change in cardiac risk after bariatric surgery. Obesity (Silver Spring) 2007;15(3):772–784. doi:10.1038/oby.2007.589.CrossRefGoogle Scholar
  14. 14.
    Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livingston EH, Nguyen NT, Li Z, Mojica WA, Hilton L, Rhodes S, Morton SC, Shekelle PG. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005;142(7):547–559.PubMedGoogle Scholar
  15. 15.
    Ali MR, Maguire MB, Wolfe BM. Assessment of obesity-related comorbidities: a novel scheme for evaluating bariatric surgical patients. J Am Coll Surg 2006;202(1):70–77. doi:10.1016/j.jamcollsurg.2005.09.014.PubMedCrossRefGoogle Scholar
  16. 16.
    Ruano M, Silvestre V, Castro R, Garcia-Lescun MC, Rodriguez A, Marco A, Garcia-Blanch G. Morbid obesity, hypertensive disease and the renin–angiotensin–aldosterone axis. Obes Surg 2005;15(5):670–676. doi:10.1381/0960892053923734.PubMedCrossRefGoogle Scholar
  17. 17.
    Sjostrom CD. Surgery as an intervention for obesity. Results from the Swedish Obese Subjects study. Growth Horm IGF Res 2003;13(Suppl A):S22–S26.PubMedCrossRefGoogle Scholar
  18. 18.
    Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 2003;237(6):751–756. discussion 757–758. doi:10.1097/00000658-200306000-00002.PubMedCrossRefGoogle Scholar
  19. 19.
    Vogel JA, Franklin BA, Zalesin KC, Trivax JE, Krause KR, Chengelis DL, McCullough PA. Reduction in predicted coronary heart disease risk after substantial weight reduction after bariatric surgery. Am J Cardiol 2007;99(2):222–226. doi:10.1016/j.amjcard.2006.08.017.PubMedCrossRefGoogle Scholar
  20. 20.
    Fernstrom JD, Courcoulas AP, Houck PR, Fernstrom MH. Long-term changes in blood pressure in extremely obese patients who have undergone bariatric surgery. Arch Surg 2006;141(3):276–283. doi:10.1001/archsurg.141.3.276.PubMedCrossRefGoogle Scholar
  21. 21.
    Sjostrom CD, Peltonen M, Wedel H, Sjostrom L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000;36(1):20–25.PubMedGoogle Scholar
  22. 22.
    Huerta S, Kohan D, Siddiqui A, Anthony T, Livingston EH. Assessment of comorbid conditions in veteran patients after Roux-en-Y gastric bypass. Am J Surg 2007;194(1):48–52. doi:10.1016/j.amjsurg.2006.11.017.PubMedCrossRefGoogle Scholar
  23. 23.
    Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: why is it so resistant to treatment. Kidney Int 2006;69(6):967–973. doi:10.1038/sj.ki.5000177.PubMedCrossRefGoogle Scholar
  24. 24.
    Hall JE. The kidney, hypertension, and obesity. Hypertension 2003;41(3):625–633. doi:10.1161/01.HYP.0000052314.95497.78.PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2008

Authors and Affiliations

  • Marcelo W. Hinojosa
    • 1
  • J. Esteban Varela
    • 2
  • Brian R. Smith
    • 1
  • Fredrick Che
    • 1
  • Ninh T. Nguyen
    • 1
    • 3
  1. 1.Department of SurgeryUniversity of California, Irvine Medical CenterOrangeUSA
  2. 2.Department of SurgeryUniversity of Texas SouthwesternDallasUSA
  3. 3.Division of Gastrointestinal SurgeryUniversity of California, Irvine Medical CenterOrangeUSA

Personalised recommendations